Asia PacificBreaking News

Nusantics secures Series A funding

Indonesia: Nusantics, an Indonesian genomics technology startup, announced today it has raised an undisclosed amount in Series A funding, led by East Ventures.

The money will be used to further enhance its R&D capability to improve its microbiome analysis and medical diagnostic kits.

Additionally, Nusantics has roped in Triawan Munaf, a Venture Advisor at East Ventures, as its Commissioner. A former Indonesian cabinet member under President Jokowi, Munaf is currently President Commissioner of flag carrier Garuda Indonesia.

Nusantics was started in 2019 with the ever-growing belief in the importance of microbiome balance in life, which is focused on providing sustainable solutions by integrating science and nature​. ​

Despite its core focus on microbiome research, the biotech startup repurposed its capability to develop COVID-19 test kits that can detect mutations of the coronavirus, including the recent UK strain.

The firm said it has partnered with state-owned biotech firm Bio Farma to produce up to three million test kits per month. First-generation test kits were also distributed to 19 provinces across Indonesia as part of the Pasti Bisa movement, a collaborative effort by East Ventures to stem the rise of the virus-19 cases in Indonesia.

Plans are underway to develop a third-generation test kit that can detect the coronavirus through salivary samples.

“We plan to develop a new test kit that can detect the COVID-19 virus in a salivary sample. This will be more efficient, less painful for users, and safer for medical practitioners. Saliva will also make infectious and less-infectious detection possible,” shared Revata Utama, CTO of Nusantics.


Related Articles

Leave a Reply

Back to top button